Similar articles for PMID: 35220240

Year	Number of Results
2011	1
2012	1
2013	6
2014	19
2015	17
2016	14
2017	18
2018	19
2019	20
2020	13
2021	14
2022	32
2023	9
2024	0

1

Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice.

Mizokami A, Nishimoto K, Matsuyama H, Ichikawa T, Takahashi S, Shiina H, Hashine K, Sugiyama Y, Kamiyama M, Enokida H, Nakajima K. Mizokami A, et al. Anticancer Res. 2022 Mar;42(3):1465-1475. doi: 10.21873/anticanres.15617. Anticancer Res. 2022. PMID: 35220240

2

Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.

Angelergues A, Efstathiou E, Gyftaki R, Wysocki PJ, Lainez N, Gonzalez I, Castellano DE, Ozguroglu M, Carbonero IG, Flechon A, Borrega P, Guillot A, Balea BC, Le Moulec S, Esteban E, Munarriz J, Rubio G, Birtle AJ, Delanoy N, Bellmunt J, Oudard S. Angelergues A, et al. Clin Genitourin Cancer. 2018 Aug;16(4):e777-e784. doi: 10.1016/j.clgc.2018.02.016. Epub 2018 Feb 23. Clin Genitourin Cancer. 2018. PMID: 29550200

3

Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.

Uemura K, Miyoshi Y, Kawahara T, Yoneyama S, Hattori Y, Teranishi J, Kondo K, Moriyama M, Takebayashi S, Yokomizo Y, Yao M, Uemura H, Noguchi K. Uemura K, et al. BMC Cancer. 2016 Feb 16;16:109. doi: 10.1186/s12885-016-2160-1. BMC Cancer. 2016. PMID: 26883015 Free PMC article.

4

The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.

Okita K, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Ito A, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. Okita K, et al. Clin Genitourin Cancer. 2020 Apr;18(2):e103-e111. doi: 10.1016/j.clgc.2019.09.006. Epub 2019 Sep 27. Clin Genitourin Cancer. 2020. PMID: 31810867

5

Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.

Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS. Oh WK, et al. Med Oncol. 2017 Aug 10;34(9):160. doi: 10.1007/s12032-017-1014-2. Med Oncol. 2017. PMID: 28795333 Free PMC article.

6

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y. Al Nakouzi N, et al. Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2. Eur Urol. 2015. PMID: 24837187

7

Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study.

Suzuki K, Matsubara N, Kazama H, Seto T, Tsukube S, Matsuyama H. Suzuki K, et al. Jpn J Clin Oncol. 2019 Dec 27;49(12):1157-1163. doi: 10.1093/jjco/hyz108. Jpn J Clin Oncol. 2019. PMID: 31361807 Free PMC article.

8

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.

Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier É, Deville JL, Goupil MG, Morales R, Thiery-Vuillemin A, Gavrikova T, Barthelemy P, Sella A, Fizazi K, Baciarello G, Fererro JM, Laguerre B, Verret B, Hans S, Oudard S. Delanoy N, et al. Eur Urol Oncol. 2018 Dec;1(6):467-475. doi: 10.1016/j.euo.2018.05.009. Epub 2018 Jun 8. Eur Urol Oncol. 2018. PMID: 31158090 Clinical Trial.

9

Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.

Bando Y, Hinata N, Terakawa T, Furukawa J, Harada KI, Nakano Y, Fujisawa M. Bando Y, et al. Med Oncol. 2017 Aug 17;34(9):163. doi: 10.1007/s12032-017-1024-0. Med Oncol. 2017. PMID: 28819719 Clinical Trial.

10

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Crawford ED, et al. J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. J Urol. 2015. PMID: 26196735 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

146 results

Results by year